Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure

CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades. 1 The one-year mortality ranges from 15 percent among relatively unselecte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 1991-08, Vol.325 (5), p.293-302
Hauptverfasser: Yusuf, Salim, Pitt, Bertram, Davis, Clarence E, Hood, William B, Cohn, Jay N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 302
container_issue 5
container_start_page 293
container_title The New England journal of medicine
container_volume 325
creator Yusuf, Salim
Pitt, Bertram
Davis, Clarence E
Hood, William B
Cohn, Jay N
description CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades. 1 The one-year mortality ranges from 15 percent among relatively unselected patients 2 to 50 percent among those in New York Heart Association functional class IV. 3 About 35 percent of all patients with a diagnosis of congestive heart failure are hospitalized every year (unpublished data). The Veterans Administration Cooperative Vasodilator Heart Failure Trial 4 reported a lower mortality in patients with congestive heart failure treated with hydralazine . . .
doi_str_mv 10.1056/NEJM199108013250501
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80636952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2836234</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-a822758183104508f8f4f2665e24b7d985bfdcf2fa0e48bdcb66f0f416a1fcf63</originalsourceid><addsrcrecordid>eNp9kVuP0zAQhS0EWkrhFyAkCxAvKDC-xn5EVcqCykXcXiPHscGVk-zaSdH-e7y02gcE-MWW55szR3MQekjgBQEhX75v3r4jWhNQQBgVIIDcQisiGKs4B3kbrQCoqnit2V10L-c9lEO4PkNnFEQNjK_QVeO9szOePG5GE81FChFPI_68pEM4mIjDiD-aObhxzvhnmH_gT65frOvxzvkZfyv_KdglmoSbfREKpXebzO9Hxmbs8WYav7s8h4PD586kGW9NiEty99Edb2J2D073Gn3dNl8259Xuw-s3m1e7ygoi5sooSmuhiGIEuADlleeeSikc5V3dayU631tPvQHHVdfbTkoPnhNpiLdesjV6dtS9SNPlUpy0Q8jWxWhGNy25VSCZ1IIW8PEf4H5aUllKbillWpC6mFijJ_-CiFaMs7omulDsSNk05Zycb8teB5OuWgLtdXbtX7IrXY9O2ks3uP6m5xRWqT891U22JvpkRhvyDca1LA6uLT4_YsOQ29Hth_8O_QWza6xh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983437719</pqid></control><display><type>article</type><title>Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Yusuf, Salim ; Pitt, Bertram ; Davis, Clarence E ; Hood, William B ; Cohn, Jay N</creator><creatorcontrib>Yusuf, Salim ; Pitt, Bertram ; Davis, Clarence E ; Hood, William B ; Cohn, Jay N ; The SOLVD Investigators ; SOLVD Investigators ; The SOLVD Investigators</creatorcontrib><description>CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades. 1 The one-year mortality ranges from 15 percent among relatively unselected patients 2 to 50 percent among those in New York Heart Association functional class IV. 3 About 35 percent of all patients with a diagnosis of congestive heart failure are hospitalized every year (unpublished data). The Veterans Administration Cooperative Vasodilator Heart Failure Trial 4 reported a lower mortality in patients with congestive heart failure treated with hydralazine . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199108013250501</identifier><identifier>PMID: 2057034</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Angina pectoris ; Angiotensin-converting enzyme inhibitors ; Arrhythmia ; Biological and medical sciences ; Blood Pressure - drug effects ; Cardiovascular system ; Cause of Death ; Chronic Disease ; Clinical trials ; Congestive heart failure ; Double-Blind Method ; Drug therapy ; Electrolytes - blood ; Enalapril - adverse effects ; Enalapril - therapeutic use ; Enzymes ; Female ; Follow-Up Studies ; Heart attacks ; Heart failure ; Heart Failure - drug therapy ; Heart Failure - mortality ; Heart Failure - physiopathology ; Hospitalization ; Humans ; Hypotheses ; Kidney - drug effects ; Male ; Medical sciences ; Middle Aged ; Mortality ; Patient Compliance ; Pharmacology. Drug treatments ; Stroke Volume ; Survival Rate ; Vasodilator agents. Cerebral vasodilators ; Ventricle</subject><ispartof>The New England journal of medicine, 1991-08, Vol.325 (5), p.293-302</ispartof><rights>1992 INIST-CNRS</rights><rights>Copyright Massachusetts Medical Society Aug 1, 1991</rights><rights>Copyright Massachusetts Medical Society, Publishing Division Aug 1, 1991</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-a822758183104508f8f4f2665e24b7d985bfdcf2fa0e48bdcb66f0f416a1fcf63</citedby><cites>FETCH-LOGICAL-c515t-a822758183104508f8f4f2665e24b7d985bfdcf2fa0e48bdcb66f0f416a1fcf63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199108013250501$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1983437719?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,2748,2749,26086,27907,27908,52365,54047,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4969838$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2057034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yusuf, Salim</creatorcontrib><creatorcontrib>Pitt, Bertram</creatorcontrib><creatorcontrib>Davis, Clarence E</creatorcontrib><creatorcontrib>Hood, William B</creatorcontrib><creatorcontrib>Cohn, Jay N</creatorcontrib><creatorcontrib>The SOLVD Investigators</creatorcontrib><creatorcontrib>SOLVD Investigators</creatorcontrib><creatorcontrib>The SOLVD Investigators</creatorcontrib><title>Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades. 1 The one-year mortality ranges from 15 percent among relatively unselected patients 2 to 50 percent among those in New York Heart Association functional class IV. 3 About 35 percent of all patients with a diagnosis of congestive heart failure are hospitalized every year (unpublished data). The Veterans Administration Cooperative Vasodilator Heart Failure Trial 4 reported a lower mortality in patients with congestive heart failure treated with hydralazine . . .</description><subject>Angina pectoris</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Arrhythmia</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular system</subject><subject>Cause of Death</subject><subject>Chronic Disease</subject><subject>Clinical trials</subject><subject>Congestive heart failure</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Electrolytes - blood</subject><subject>Enalapril - adverse effects</subject><subject>Enalapril - therapeutic use</subject><subject>Enzymes</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - physiopathology</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Kidney - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Patient Compliance</subject><subject>Pharmacology. Drug treatments</subject><subject>Stroke Volume</subject><subject>Survival Rate</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><subject>Ventricle</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kVuP0zAQhS0EWkrhFyAkCxAvKDC-xn5EVcqCykXcXiPHscGVk-zaSdH-e7y02gcE-MWW55szR3MQekjgBQEhX75v3r4jWhNQQBgVIIDcQisiGKs4B3kbrQCoqnit2V10L-c9lEO4PkNnFEQNjK_QVeO9szOePG5GE81FChFPI_68pEM4mIjDiD-aObhxzvhnmH_gT65frOvxzvkZfyv_KdglmoSbfREKpXebzO9Hxmbs8WYav7s8h4PD586kGW9NiEty99Edb2J2D073Gn3dNl8259Xuw-s3m1e7ygoi5sooSmuhiGIEuADlleeeSikc5V3dayU631tPvQHHVdfbTkoPnhNpiLdesjV6dtS9SNPlUpy0Q8jWxWhGNy25VSCZ1IIW8PEf4H5aUllKbillWpC6mFijJ_-CiFaMs7omulDsSNk05Zycb8teB5OuWgLtdXbtX7IrXY9O2ks3uP6m5xRWqT891U22JvpkRhvyDca1LA6uLT4_YsOQ29Hth_8O_QWza6xh</recordid><startdate>19910801</startdate><enddate>19910801</enddate><creator>Yusuf, Salim</creator><creator>Pitt, Bertram</creator><creator>Davis, Clarence E</creator><creator>Hood, William B</creator><creator>Cohn, Jay N</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19910801</creationdate><title>Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure</title><author>Yusuf, Salim ; Pitt, Bertram ; Davis, Clarence E ; Hood, William B ; Cohn, Jay N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-a822758183104508f8f4f2665e24b7d985bfdcf2fa0e48bdcb66f0f416a1fcf63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Angina pectoris</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Arrhythmia</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular system</topic><topic>Cause of Death</topic><topic>Chronic Disease</topic><topic>Clinical trials</topic><topic>Congestive heart failure</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Electrolytes - blood</topic><topic>Enalapril - adverse effects</topic><topic>Enalapril - therapeutic use</topic><topic>Enzymes</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - physiopathology</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Kidney - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Patient Compliance</topic><topic>Pharmacology. Drug treatments</topic><topic>Stroke Volume</topic><topic>Survival Rate</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yusuf, Salim</creatorcontrib><creatorcontrib>Pitt, Bertram</creatorcontrib><creatorcontrib>Davis, Clarence E</creatorcontrib><creatorcontrib>Hood, William B</creatorcontrib><creatorcontrib>Cohn, Jay N</creatorcontrib><creatorcontrib>The SOLVD Investigators</creatorcontrib><creatorcontrib>SOLVD Investigators</creatorcontrib><creatorcontrib>The SOLVD Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yusuf, Salim</au><au>Pitt, Bertram</au><au>Davis, Clarence E</au><au>Hood, William B</au><au>Cohn, Jay N</au><aucorp>The SOLVD Investigators</aucorp><aucorp>SOLVD Investigators</aucorp><aucorp>The SOLVD Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1991-08-01</date><risdate>1991</risdate><volume>325</volume><issue>5</issue><spage>293</spage><epage>302</epage><pages>293-302</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades. 1 The one-year mortality ranges from 15 percent among relatively unselected patients 2 to 50 percent among those in New York Heart Association functional class IV. 3 About 35 percent of all patients with a diagnosis of congestive heart failure are hospitalized every year (unpublished data). The Veterans Administration Cooperative Vasodilator Heart Failure Trial 4 reported a lower mortality in patients with congestive heart failure treated with hydralazine . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>2057034</pmid><doi>10.1056/NEJM199108013250501</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 1991-08, Vol.325 (5), p.293-302
issn 0028-4793
1533-4406
language eng
recordid cdi_proquest_miscellaneous_80636952
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine
subjects Angina pectoris
Angiotensin-converting enzyme inhibitors
Arrhythmia
Biological and medical sciences
Blood Pressure - drug effects
Cardiovascular system
Cause of Death
Chronic Disease
Clinical trials
Congestive heart failure
Double-Blind Method
Drug therapy
Electrolytes - blood
Enalapril - adverse effects
Enalapril - therapeutic use
Enzymes
Female
Follow-Up Studies
Heart attacks
Heart failure
Heart Failure - drug therapy
Heart Failure - mortality
Heart Failure - physiopathology
Hospitalization
Humans
Hypotheses
Kidney - drug effects
Male
Medical sciences
Middle Aged
Mortality
Patient Compliance
Pharmacology. Drug treatments
Stroke Volume
Survival Rate
Vasodilator agents. Cerebral vasodilators
Ventricle
title Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T02%3A37%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Enalapril%20on%20Survival%20in%20Patients%20with%20Reduced%20Left%20Ventricular%20Ejection%20Fractions%20and%20Congestive%20Heart%20Failure&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Yusuf,%20Salim&rft.aucorp=The%20SOLVD%20Investigators&rft.date=1991-08-01&rft.volume=325&rft.issue=5&rft.spage=293&rft.epage=302&rft.pages=293-302&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199108013250501&rft_dat=%3Cproquest_cross%3E2836234%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983437719&rft_id=info:pmid/2057034&rfr_iscdi=true